Ghassan K. Abou-Alfa MD, MBAAttending Physician, Memorial Sloan Kettering Cancer Center; Professor, Weill Medical College at Cornell University, New York, New York
Ghassan Abou-Alfa is an Attending Physician at Memorial Sloan Kettering Cancer Center (MSK) and Professor of Medicine at Weill Medical School at Cornell University. He completed his residency and fellowship at Yale University, and later joined the Yale faculty. He received an MBA from Columbia University. Professor Abou-Alfa served as Chair of the National Cancer Institute (NCI) Hepatobiliary Task Force for two consecutive terms; and is member of the NCI AIDS Malignancy Consortium Steering Committee. Professor Abou-Alfa is the President for the International Society of Gastrointestinal Oncology is a trustee of the American University of Beirut; and serves on the American Society of Oncology (ASCO) International Affairs Committee.
Professor Abou-Alfa specializes in in the treatment of gastrointestinal malignancies with extensive expertise in hepatocellular carcinoma (HCC), cholangiocarcinoma, gallbladder cancer, and fibrolamellar carcinoma (FLC). Professor Abou-Alfa’s research focuses on advancing checkpoint inhibitors and small biological molecules into standard cancer therapies, determining the right CAR-T antigens for HCC and FLC, and analyzing international patient biographies to help determine the appropriate therapy. Under the auspices of the MSK International Center, Professor Abou-Alfa, helped establish, maintain, and flourish a strong global relationship with different institutions worldwide.
DisclosuresDr. Abou-Alfa reports the following:
- Research support from ActaBiologica, Agios, Astra Zeneca, Bayer, Beigene, Berry Genomics, BMS, Casi, Celgene, Exelixis, Genentech, Halozyme, Incyte, Mabvax, Polaris, Puma, QED, Roche, and Sillajen.
- Consulting for Agios, Astra Zeneca, Autem, Bayer, Beigene, Berry Genomics, Celgene, CytomX, Debio, Eisai, Eli Lilly, Flatiron, Genentech, Gilead, Incyte, Ipsen, LAM, Loxo, Merck, MINA, QED, Redhill, Roche, Silenseed, Sillajen, Sobi, Therabionics, Twoxar, Vector, and Yiviva.